Question 1

What do peptides actually do?

Accepted Answer

There is no single answer available, and the reason for that is the genuinely useful part of the question. A 2026 sports-medicine review describes peptides as short chains of amino acids occupying a niche between small-molecule drugs and large proteins, which is a statement about size and handling rather than about effect. The same review runs through twelve of them in one list, approved and unapproved side by side, from a growth-hormone fragment to a copper-bound tripeptide. What each one has been measured doing is a separate question with a separate literature behind it, and the answers do not transfer between them. A result in a mouse joint settles nothing about appetite in an adult, and a weight figure from a phase 3 trial settles nothing about tendon repair, which is why the only question worth asking is the narrower one: a single outcome at a time, which compounds have been measured against it, in what species, and over how many weeks. That is how the sections below are arranged, and how the compound pages listed above are arranged too.

Question 2

What is the difference between peptides and GLP-1s?

Accepted Answer

They are not two categories. One sits inside the other, and the confusion is worth clearing up before anything else on this page. GLP-1 is a hormone the body already makes: a 2019 review describes glucagon-like peptide-1 as an incretin hormone with important effects on glycemic control and body weight regulation, which chemists then worked on so it would last long enough to be given as a medicine. Everything built from it is a peptide, so every GLP-1 receptor agonist belongs in this category, while most of the category has nothing to do with GLP-1. Ozempic sits in that overlap. Semaglutide is sold under more than one brand name for more than one indication, and a 2022 review covers the Wegovy brand of semaglutide for chronic weight management. This is why a yes-or-no verdict on peptides is never available: the same word covers an injection trialled in thousands of randomised adults and an unlabelled vial whose whole record is rodent work. The class-level record for the incretin family is gone through on the GLP-1 benefits page.

Question 3

Do peptides actually work?

Accepted Answer

Work at what, and measured against what? Those two questions are what separate these compounds from one another, and a 2026 review of the growth-hormone peptides does the most useful thing anyone has done with them: it sorts them into evidence tiers running from regulatory-grade randomised trial data at one end to a complete absence of human studies at the other. That single sentence is the shape of the whole field. At one end are compounds with phase 3 programmes, placebo groups, scheduled endpoints and thousands of randomised adults. At the other are compounds whose entire record is animal work. A 2026 sports-medicine review puts it plainly: many unapproved peptides produce favourable tissue repair and metabolic outcomes in animal models, while rigorous human safety data are scarce and there is potential for serious harm. Both ends of that range are sold under the same word, which is why any yes-or-no answer about peptides is wrong in one direction or the other, and why the sections below keep the two ends of the distribution apart deliberately.

Question 4

Do peptides really work for weight loss?

Accepted Answer

For one family of them the record is about as full as this field gets. A 2025 review pooled 26 randomised trials in 15,491 adults with overweight or obesity and no diabetes. Compared with placebo, tirzepatide reached weight loss of up to 17.8% after 72 weeks of therapy, semaglutide up to 13.9% after 68 weeks, and liraglutide up to 5.8% after 26 weeks. Retatrutide, which is not approved, produced greater weight loss of up to 22.1% after 48 weeks. Outside that family the picture changes. MOTS-c prevented diet-induced obesity in mice, in the 2015 paper that first named the peptide. That is prevention in animals on a set diet, not weight lost by an adult who is already heavy. Collagen peptides reduced ad libitum energy intake at a subsequent meal in a randomised crossover trial in active females, which is an appetite reading over one day. Each molecule has a page of its own: The Semaglutide benefits page, the Tirzepatide benefits page and the Retatrutide benefits page.

Question 5

Can one peptide be compared with another for weight loss?

Accepted Answer

Inside the incretin family, partly. A 2025 open-label phase 3b trial randomised adults with obesity but without type 2 diabetes to tirzepatide or semaglutide for 72 weeks. A total of 751 participants were randomised, and the primary endpoint was the percent change in weight from baseline to week 72. A 2026 network meta-analysis then set tirzepatide, liraglutide and semaglutide on one axis, using six of 42 randomised controlled trials that survived a stringent heterogeneity assessment. Across families, nothing of that kind has been run. The 2025 systematic review of 26 weight trials reports that no head-to-head RCTs were available among the work it searched, and none of the studies covered here gives one of these compounds and a tissue-repair peptide to comparable people and measures the same endpoint. So the gap between, say, an incretin and BPC-157 is not a narrow margin between rivals; they are different questions asked in different species, and no arithmetic closes that. How the incretins line up against each other is worked through on the GLP-1 comparison page.

Question 6

What are the top five peptides to take?

Accepted Answer

There is no such list here, and the reason is not caution. A ranking needs one measure applied to every item on it, and that measure does not exist across these compounds. What would have to be run is a study giving two of them to comparable people and recording the same endpoint, which among the research behind this page has happened between two incretins and nowhere else. A list would therefore be setting a 72-week endpoint in randomised adults beside a result in a rodent. To take the most-searched example: when the BPC-157 literature was last counted in a 2025 systematic review, 36 studies were included, of which 35 were preclinical and one clinical — and ordering two bodies of work that dissimilar produces a sequence rather than a finding. The 2026 growth-hormone review makes the same point from the clinical side, highlighting the resulting uncertainty around putative performance and recomposition benefits. What is actually useful is duller: for one outcome, which compounds were measured, in which species, over how many weeks, and what was left unmeasured.

Question 7

Do peptides really work for healing?

Accepted Answer

This is where the distance between public interest and measured evidence is widest. A 2025 systematic review searched the BPC-157 literature to June 2024 and identified a total of 544 articles from 1993 to 2024. In preclinical models, that review reports, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bony injuries. Four tissue types is a broad signal, and all of it is an animal signal. The same review states that no clinical safety data were found. The human side is three pilot studies. A 2025 narrative review counts exactly that: intraarticular knee pain, interstitial cystitis, and intravenous safety work. Three pilots are not a smaller version of the animal evidence; they answer smaller questions, under conditions the animal experiments never had to meet, and they carry the weight of pilots rather than of confirmation. The BPC-157 benefits page goes through that record study by study, and the tissue-repair claims made for the unapproved compounds as a group are the ones the 2026 sports-medicine review places in animal models.

Question 8

Which peptides have been measured against inflammation?

Accepted Answer

Several, though never against inflammation on its own. No study covered here used inflammation as an endpoint in a person: what the experiments measured were particular named diseases, mostly in rodents, with inflammatory markers read out at the end rather than symptoms a reader would recognise. Three sets of work carry most of this. In a mouse model of osteoarthritis, imaging and tissue scoring recorded that MOTS-c delayed the loss of joint cartilage. In mice dosed with bleomycin, which scars the lung, SS-31 (elamipretide) reduced inflammatory factor expression in lung tissue. A 2025 review of BPC-157 describes effects in preclinical models of tissue injury, bowel disease and brain disorders. That is three separate diseases in three sets of animals, which is a different claim from the one a person with a painful shoulder is making with the same word. The outcome-level detail for each sits on the MOTS-c benefits page and the SS-31 benefits page, and the single inflammatory marker measured inside a phase 3 programme is handled on the Tirzepatide benefits page.

Question 9

Do peptides actually work for anti-ageing?

Accepted Answer

A 2026 review of peptides in ageing is the nearest thing to a map. Nine peptides were identified spanning diverse aging interventions, from metabolism and skin to tissue repair and sexual function. The same review records that the non-approved ones had limited clinical evidence and lack long-term safety data. That line is what separates the nine from one another. The human end of this is skin, and it is mostly collagen. In a 2025 randomised, placebo-controlled trial, 70 healthy adults took a collagen peptide or a placebo for 8 weeks. Skin was measured with instruments and expert visual scoring at five time points. Elasticity, surface and deep hydration and dermal density all moved in the test group. The animal end is mitochondrial. In mice treated from 18 months of age, elamipretide improved the physical performance of males and the cognitive performance of females. One 2018 review runs the other way: humanin and MOTS-c exacerbate the senescence-associated secretory phenotype — the inflammatory signals worn-out cells give off. Trial by trial, the skin work is on the Collagen benefits page and the elamipretide endpoints on the SS-31 benefits page. Every peptide measured on skin, by route, is gathered on the peptides-for-skin overview.

Question 10

Which peptides have been measured for muscle growth?

Accepted Answer

Fewer than the marketing suggests, and the clear results point two ways at once. The growth-hormone peptides are the ones sold for this, and a 2026 review of them is blunt: none is approved for physique or performance use, and what is in the vial, how much of it, and what it is stacked with are all uncertain in an unregulated supply chain. The one approved lean-mass indication anywhere in that family is unusually narrow. A 2006 review calls somatropin the only US-approved option indicated to increase lean body mass, bodyweight and physical endurance in HIV-associated wasting, which is a wasting illness rather than a training goal. Where randomised numbers exist, they come from collagen, and they are modest. In a trial of older men with sarcopenia who did twelve weeks of resistance training, collagen peptides improved body composition by raising fat-free mass and muscle strength against placebo. A second trial ran 16 weeks in fifty healthy young sedentary males, and it asked whether daily collagen peptides affect muscle and tendon stiffness and explosive muscle strength. Meanwhile the compounds with the largest weight figures also subtract muscle. In a network meta-analysis in which twenty-two randomized controlled trials were included, lean mass loss made up about a quarter of the total weight lost. The HGH benefits page and the IGF-1 benefits page carry the growth-hormone side; the Collagen benefits page carries the training trials. The whole muscle record, compound by compound, is laid out on the peptides-for-muscle-growth overview.

Question 11

Who was enrolled in the studies that measured a benefit?

Accepted Answer

Almost nobody who did not already have the condition. The semaglutide weight trial enrolled 1,961 adults with a body-mass index of 30 or greater, or 27 or greater in persons with at least one weight-related coexisting condition, who did not have diabetes. The tirzepatide obesity trial assigned 2,539 adults on the same entry rule, excluding diabetes. The largest growth-hormone dataset is a registry whose full cohort of 83,803 children was treated for growth disorders. The bremelanotide phase 3 programme ran in premenopausal women with hypoactive sexual desire disorder, and most participants were white (85.6%), from U.S. sites (96.6%). Read as a set, that is the most important limitation on everything above: each result belongs to people who satisfied an entry criterion, and whether something works is a different question when it is asked by somebody who satisfies none of them. A reader who is not carrying obesity, not deficient in growth hormone and not diagnosed with a desire disorder sits outside every population named on this page, which is not a reason to discount the findings so much as the reason they do not transfer. What the desire-disorder questionnaires actually scored is weighed on the PT-141 benefits page.

Question 12

Does a trial result belong to every version of a molecule?

Accepted Answer

No, and this is the quietest way a reader ends up misled: a measured outcome belongs to the material that was administered in the study, manufactured to a filed specification, supplied for that particular trial, and accounted for afterwards. None of that documentation travels automatically to a vial purchased elsewhere that carries the same name on its label. FDA enforcement listings make the point with three entries that have nothing else in common: a compounded Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial; Tirzepatide Injections, 30mg/mL, pre-filled syringe; and BPC-157 for Injection, 15mg/10mL vial. The reason recorded against all three is Lack of Assurance of Sterility. Two of those molecules carry phase 3 programmes behind them and the third is preclinical, so the finding is about a particular vial rather than about a compound, and it says nothing about whether any of them works. What a buyer can check for themselves is set out compound by compound, starting at the Semaglutide sourcing page and the BPC-157 sourcing page.

Question 13

What can a celebrity's peptide routine tell you?

Accepted Answer

Very little, and that is a statement about study design rather than about any person. A 2026 sports-medicine review addresses the pattern head-on: it discusses the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect. A routine reported second-hand has one participant, no control arm, no blinding, no verified contents and no record of what else changed that year, so it cannot separate a compound from expectation or from everything surrounding it. This site does not report who is said to take what, and no name is attached to a protocol anywhere on it. The useful version of that curiosity is the same question put to the literature: which compound, measured against which outcome, in whom, over how long. For some compounds on this page all four answers exist; for others none of them does, and that difference carries more information than any routine. A 2026 gerontology review reaches the same place from the clinical side, listing significant knowledge gaps including optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy.

Question 14

What is the downside of taking peptides?

Accepted Answer

The class answer is that harm is measured as unevenly as benefit, and it runs the same way. For the approved compounds, adverse events were collected inside the same randomised trials that produced the weight figures above. Both sides of the ledger come from one place and can be read against each other. For the unapproved ones, the benefit claims come from animal experiments while the harm reports come from clinics, so the two halves of the picture were never gathered by the same method. A 2026 review of the growth-hormone peptides catalogues what actually turns up in clinic. The list is specific: endocrine and metabolic disturbances, meaning raised prolactin and cortisol, appetite changes and blood sugar moving out of range, alongside fluid retention, aching muscles and joints, and reactions at the injection site. Those are effects seen in people taking compounds whose benefit evidence sits largely in rodents. That gap between the two halves is the thing worth carrying away from this page. The documented adverse-effect record is kept compound by compound rather than summed up: The GLP-1 safety page for the incretin class, and the BPC-157 safety page for the most-asked unapproved one.

Peptides for weight loss, healing and ageing